First and largest statin trial in renal transplant patients demonstrates that Lescol® reduces cardiac death and heart attack
ALERT results presented at American Transplant Congress and published on-line in The Lancet
Basel, 3 June 2003 - Lescol® (fluvastatin sodium) significantly reduces the combined incidence of cardiac death or non-fatal myocardial infarction (MI) in renal transplant patients compared to placebo, according to results of the Assessment of Lescol in Renal Transplantation (ALERT) study published today in the online version of The Lancet and being presented today at the American Transplant Congress, the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.
Please see full press release under the following link:
